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How to Move From Belief to Proof? Articulating the Value
of Chronic Disease and Care Management Programs
for Adults With Asthma
Scientific research has generated a convincing evidence
base for showing that the majority of chronically ill pa-
tients, including many with asthma or chronic obstructive
pulmonary disease, are nowadays not receiving the care
they need, because our present models of care delivery are
not equipped to effectively and efficiently address their
demands.1 Moreover, studies have demonstrated that most
Western health-care systems are in their current form un-
sustainable for a future characterized by an increasing hu-
man, clinical, and economic burden of respiratory and other
chronic conditions.1-4
In response to this, health-care organizations have im-
plemented a wide spectrum of chronic disease and care
management programs to improve care processes and out-
comes while making more efficient use of scarce health-
care resources. The aim of these programs is to transform
care of chronic illness from acute and reactionary to pro-
active, planned, and population-based. This should be ac-
complished through more effective team care and planned
interactions; intensified self-management support bolstered
by more effective use of community resources; integrated
decision support; and wider and better use of patient reg-
istries and other supportive information and communica-
tion technology.5
Notwithstanding the intuitive appeal of this approach,
the current evidence regarding its impact on clinical, hu-
man, and economic outcomes is severely limited by the
number and quality of the existing studies. Although some
studies,6-12 have found positive results with regard to some
aspects of quality of care (eg, improved disease control,
adherence to evidence-based guidelines, and patient satis-
faction), results on clinical and economic outcomes remain
far below expectations.6,9 Indeed, despite relentless efforts
and investments, the enthusiasts behind chronic disease
and care programs keep struggling to articulate their over-
all value to patients, care providers, and payers in terms of
“proof” rather than “belief.”5,9
But why is it so difficult to show the added value, if any,
of these interventions? Do disease and care management
programs simply not work as well as many believed they
would? Or have the research efforts made so far been
largely inadequate to reveal the true impact of disease and
care management programs, whether this be positive or
negative?
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This issue of RESPIRATORY CARE features a study by
Maciejewski et al,13 which indeed shows that there have
been only a few well-designed evaluation studies of
disease-management programs for adults with asthma. That
finding parallels the results of other reviews, including
programs for various chronic conditions. Of special inter-
est is the review of Lemmens et al,14 which found the
methodological quality of asthma disease-management
studies particularly poor, compared to evaluations of
disease-management programs for other conditions. One
of the reasons for this might be that asthma programs are,
more often than programs for other conditions, carried out
(in part) in a community setting instead of a clinical set-
ting.15 This generally complicates the conduct of rigorous
randomized controlled trials.16 Whereas Maciejewski et al
recommend that more randomized controlled trials (RCTs)
should be undertaken before recommendations about any
particular program are made, Lemmens et al14 point out
that in organizational research RCTs are often impossible
to implement. Therefore, if an RCT is practically impos-
sible, the next best design that minimizes potential bias
(internal validity), maximizes generalizability (external va-
lidity), and is feasible in practice, should be chosen. This
would be a first step to better articulate the value of asthma
disease and care management programs in everyday prac-
tice. As Maciejewski et al rightly point out, studies with
quasi-experimental or otherwise flawed designs (which
may also include RCTs) should pay more attention to em-
ploying the appropriate statistical techniques to correct for
potential biases, for example, caused by not randomizing
on patient-level.
Another challenge to demonstrating the value of
asthma disease-management programs is choosing the
“right” measures to evaluate a program’s impact. Since
disease-management programs are likely to affect struc-
tures, processes, and outcomes of care, all 3 types of
indicators should be measured. Only by relating the
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changes in structures, processes, and outcomes of care
can we understand how a program generates value in
terms of effectiveness and/or efficiency of asthma care.17
Moreover, indicators should be chosen that are both
sensitive enough to detect a change stemming from the
program components within the time frame of the study,
and are associated with the expected (longer term)
changes in outcomes of care. Although that may sound
all too obvious, reviews have indicated that in about
40% of studies on disease-management, including stud-
ies of asthma disease management, there was no link
between the aims and contents of the programs and the
evaluated structure, process, and outcome indicators.17
Maciejewski et al13 contribute new insight into the
structure, process, and outcomes of asthma disease-
management programs by providing a detailed account
of the specific components of asthma disease-manage-
ment programs, the providers involved, and the collab-
oration models used to improve the management and
coordination of care. They show that, while the pro-
grams’ outcomes differed strongly, partly resulting from
differences in study design, the process outcomes con-
sistently improved following implementation of asthma
disease management, regardless of study design. This
robust finding is highly encouraging in a field charac-
terized by differences in methods (eg, study design,
measures applied, duration of follow-up, populations
studied) and in program content, provider collaboration
model, and characteristics of the surrounding health-
care setting and system.18
Nevertheless, when faced with the question, “Is there
added value from asthma disease-management programs
on human, clinical, and economic outcomes of care?”
the only answer we can justify today is, “It depends.”
The effectiveness and cost-effectiveness of any inter-
vention is conditional upon who receives what and un-
der what circumstances, and in the case of asthma dis-
ease-management programs we have yet to clearly
determine the relationships between those factors. Thus,
Maciejewski et al are quite right in their conclusion that
current evidence is insufficient to recommend any par-
ticular program.
However, considering the mounting health-care costs
and the fact that innovative industries and health-care
practices are greatly outpacing academic research on
disease management, there is an urgent need to deter-
mine the potential impact of asthma disease manage-
ment and care management programs on effectiveness
and cost effectiveness, even in the absence of “perfect”
clinical and economic data. Validated methods for so
doing exist and their application to respiratory disease
and care management programs has been published.19,20
But empirical and review studies, such as that by Ma-
ciejewski et al, on the relationship between the struc-
tures, processes, and outcomes of disease and care man-
agement, are of utmost importance to effectively “move
from belief to proof,” as regards the added value of
asthma disease-management programs.
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